

| | |
|-------------------------|---|
| 1. Record Nr. | UNINA9910717369903321 |
| Autore | Bloomfield Hanna E. |
| Titolo | Predictors and consequences of severe hypoglycemia in adults with diabetes : a systematic review of the evidence // Hanna E. Bloomfield [and seven others] |
| Pubbl/distr/stampa | Washington, District of Columbia : , : Department of Veterans Affairs (US), , [2012] ©2012 |
| Descrizione fisica | 1 online resource (iii, 163 pages) : illustrations |
| Disciplina | 616.462025 |
| Soggetti | Diabetics Diabetics - Diet therapy United States |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Note generali | "Evidence-based synthesis program." "April 2012." |
| Nota di bibliografia | Includes bibliographical references. |
| Sommario/riassunto | Prevalence of type 2 diabetes is increasing at an alarming pace, fueled by the rising rates of overweight and obesity in many populations. In the VA healthcare system, the prevalence of diabetes was 20% in fiscal year 2000 and is now estimated at nearly 25%. Although people with diabetes have a substantially increased risk of cardiovascular disease (CVD), recent trials show that intensive glucose lowering does not reduce the risk of CVD death or all-cause mortality although it reduces the risk of microvascular complications (nephropathy, retinopathy and neuropathy) and possibly non-fatal myocardial infarction. Intensive glucose control also increases the risk of hypoglycemic episodes. Several recent meta-analyses of the trials comparing intensive to conventional glucose control concluded that intensive control is associated with a 2-2.5 fold increased risk of severe hypoglycemia. The reviews however have not included smaller randomized trials, trials focused on the comparison of specific drug regimens, and non-randomized trials. We conducted the current review to provide broader |

insight into the incidence of, the risk factors for, and the clinical and social impact of severe hypoglycemia in adults with type 2 diabetes treated with glucose lowering medications.
